Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BNTC Benitec Biopharma

Pre-Market Trading 07-02 04:30:48 EDT

7.26

+0.27

+3.92%

High7.51	Low6.91	Vol30.24K
Open6.91	D1 Closing6.99	Amplitude8.66%
Mkt Cap68.05M	Tradable Cap43.64M	Total Shares9.37M
T/O217.65K	T/O Rate0.50%	Tradable Shares6.01M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BNTC","market":"US","secType":"STK","nameCN":"Benitec Biopharma","latestPrice":7.264,"timestamp":1719864000000,"preClose":6.99,"halted":0,"volume":30237,"delay":0,"floatShares":6007700,"shares":9367485,"eps":-9.648513,"marketStatus":"Pre-Market Trading","change":0.274,"latestTime":"07-02 04:30:48 EDT","open":6.905,"high":7.51,"low":6.905,"amount":217654.3575,"amplitude":0.086552,"askPrice":11.82,"askSize":200,"bidPrice":2.96,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-9.648513,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1719927000000},"marketStatusCode":1,"adr":1,"adrRate":200,"listingDate":1439870400000,"exchange":"NASDAQ","adjPreClose":7.39,"postHourTrading":{"tag":"盘后","latestPrice":7.39,"preClose":7.264,"latestTime":"16:00 EDT","volume":70,"amount":517.3,"timestamp":1719864001303},"volumeRatio":3.5520288366521955,"impliedVol":4.2015,"impliedVolPercentile":0.3125},"requestUrl":"/m/hq/s/BNTC/tweets","defaultTab":"tweets","newsList":[{"id":"2448928129","title":"Benitec Biopharma Welcomes Kishan Mehta to Its Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2448928129","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448928129?lang=en_us&edition=fundamental","pubTime":"2024-07-02 05:03","pubTimestamp":1719867818,"startTime":"0","endTime":"0","summary":"Benitec Biopharma (BNTC) has issued an update. Benitec Biopharma Inc. has enhanced its Board of Directors by appointing Kishan Mehta as a new indep...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/benitec-biopharma-welcomes-kishan-mehta-to-its-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/benitec-biopharma-welcomes-kishan-mehta-to-its-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTC","BK4139"],"gpt_icon":0},{"id":"2448399363","title":"Press Release: Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2448399363","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448399363?lang=en_us&edition=fundamental","pubTime":"2024-07-01 19:00","pubTimestamp":1719831600,"startTime":"0","endTime":"0","summary":"HAYWARD, Calif., July 01, 2024  -- Benitec Biopharma Inc.  , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary \"Silence and Replace\" DNA-directed RNA interference  platform, today announces the appointment of Kishen Mehta to the board of directors  of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity  financing announced on April 18 , led by long-term investor Suvretta Capital, where he serves as portfolio manager.\"I have been looking forward to joining Benitec's board and contributing to its success during this pivotal time for the Company,\" Mr. Mehta commented. \"Together we will focus on the mission of bringing an effective treatment option to OPMD patients.\". BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1  and two sm","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC","BHVN","LU1093756168.USD","LU1093756325.SGD"],"gpt_icon":0},{"id":"2443703085","title":"Piper Sandler Initiates Benitec Biopharma With Overweight Rating, $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2443703085","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443703085?lang=en_us&edition=fundamental","pubTime":"2024-06-13 17:40","pubTimestamp":1718271643,"startTime":"0","endTime":"0","summary":"(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)Price: 7.36, Change: -0.11, Percent Change: -1.47","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BNTC"],"gpt_icon":0},{"id":"2443572501","title":"Buy Rating on Benitec Biopharma: Promising Prospects for OPMD Treatment with BB-301","url":"https://stock-news.laohu8.com/highlight/detail?id=2443572501","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443572501?lang=en_us&edition=fundamental","pubTime":"2024-06-13 16:56","pubTimestamp":1718268994,"startTime":"0","endTime":"0","summary":"Benitec Biopharma (BNTC) has received a new Buy rating, initiated by Piper Sandler analyst, Yasmeen Rahimi. Yasmeen Rahimi has given his Buy rating...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-on-benitec-biopharma-promising-prospects-for-opmd-treatment-with-bb-301?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-on-benitec-biopharma-promising-prospects-for-opmd-treatment-with-bb-301?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTC"],"gpt_icon":0},{"id":"2437194127","title":"CureVac: Remains A Hold Based On Bird Flu Vaccine And Oncology Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2437194127","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437194127?lang=en_us&edition=fundamental","pubTime":"2024-05-24 04:47","pubTimestamp":1716497234,"startTime":"0","endTime":"0","summary":"CureVac N.V. is developing an avian influenza [H5N1] vaccine with GSK plc; A phase 1 study is already underway to evaluate this vaccine.It is working on a seasonal influenza vaccine, but further optim","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4695362-curevac-remains-a-hold-based-on-bird-flu-vaccine-and-oncology-advancements","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU0868494617.USD","IE00B19Z3581.USD","LU1023059063.AUD","CVAC","SG9999003800.SGD","BK4139","LU1066053197.SGD","BK4532","SG9999013999.USD","BK4533","BNTC","SGXZ57979304.SGD","LU1829250122.USD","IE0002270589.USD","LU0456855351.SGD","LU0058720904.USD","PFE","LU1057294990.SGD","BK4592","SG9999001176.USD","BK4581","BK4534","IE00B19Z3B42.SGD","IE00BBT3K403.USD","BK4551","BK4585","BK4007","IE00BLSP4452.SGD","LU0234572021.USD","SG9999002224.SGD","BK4550","LU0289739699.SGD","LU0122379950.USD","BK4568","GSK.UK","SG9999001176.SGD","BK4548","SG9999002232.USD","IE00BLSP4239.USD","BK4588","GSK","LU0170899867.USD","LU1066051498.USD","SG9999011175.SGD"],"gpt_icon":0},{"id":"2436547149","title":"Buy Rating for Benitec Biopharma on Promising Early-Stage Clinical Data and Solid Financials","url":"https://stock-news.laohu8.com/highlight/detail?id=2436547149","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2436547149?lang=en_us&edition=fundamental","pubTime":"2024-05-20 12:25","pubTimestamp":1716179132,"startTime":"0","endTime":"0","summary":"Benitec Biopharma (BNTC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Silvan Tuerkcan fr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-for-benitec-biopharma-on-promising-early-stage-clinical-data-and-solid-financials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-for-benitec-biopharma-on-promising-early-stage-clinical-data-and-solid-financials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","BNTC","BK4139"],"gpt_icon":0},{"id":"2435330534","title":"FFIE, OGEN and CCLD among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2435330534","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435330534?lang=en_us&edition=fundamental","pubTime":"2024-05-14 01:30","pubTimestamp":1715621451,"startTime":"0","endTime":"0","summary":"Gainers: CareCloud  +77%. Gamestop Corporation  +64%. AMC Entertainment Holdings  +48%. Novavax  +50%. Tupperware Brands Corporation  +43%. AC Immune  +39%. Faraday Future Intelligent Electric  +34%. VinFast Auto Ltd.  +31%. Macrogenics  +31%.  Koss Corp.  +29%.  Losers: TransCode Therapeutics  -43%. Seritage Growth Properties  -31%. Amprius Technologies  -28%. Antelope Enterprise Holdings Ltd  -25%. 1847 Holdings LLC  -23%. Telesis Bio  -18%. Benitec Biopharma  -17%. Oragenics  -17%. Strong Global Entertainment  -16%. Fortrea Holdings  -16%.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105333-ffie-ogen-and-ccld-among-mid-day-movers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["MGNX","BK4568","BK4577","AEHL","BK4099","BK7063","AMC","BK4108","BK4585","FFIE","BK4078","SRG","RNAZ","FTRE","ACIU","BK4233","BNTC","CCLD","BK7055","BK4080","SGE","NVAX","AMC.AU","BK4205","BK4206","GME","TUP","BK4076","BK4547","BK4139","BK4121","BK4167","EFSH","BK4180","BK4077","VFS","BK4588","AMPX","TBIO","BK4590","BK4096","OGEN","BK4086","BK4555","KOSS","BK4157","SRG.AU","BK4539"],"gpt_icon":0},{"id":"2435371849","title":"Benitec GAAP EPS of -$1.64","url":"https://stock-news.laohu8.com/highlight/detail?id=2435371849","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435371849?lang=en_us&edition=fundamental","pubTime":"2024-05-13 22:28","pubTimestamp":1715610501,"startTime":"0","endTime":"0","summary":"Benitec press release : Q3 GAAP EPS of -$1.64. Net loss attributable to shareholders was $4.3 million, compared to a net loss of $4.4 million a year-ago.  As of March 31, the company had $14.1 million in cash and cash equivalents.  Total revenues for the quarter ended March 31 were $0 compared to $54,000 in licensing revenues collected for the year-ago period.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105232-benitec-gaap-eps-of-1_64","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","BNTC"],"gpt_icon":0},{"id":"2435220324","title":"Benitec Biopharma Q3 2024 Revenue $0 Down From $54,000 YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2435220324","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435220324?lang=en_us&edition=fundamental","pubTime":"2024-05-13 20:19","pubTimestamp":1715602752,"startTime":"0","endTime":"0","summary":"Revenue $0 Down From","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38787553/benitec-biopharma-q3-2024-revenue-0-down-from-54-000-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC"],"gpt_icon":0},{"id":"2435324272","title":"Benitec Biopharma Q3 2024 GAAP EPS $(1.64) Misses $(0.78) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2435324272","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435324272?lang=en_us&edition=fundamental","pubTime":"2024-05-13 20:18","pubTimestamp":1715602728,"startTime":"0","endTime":"0","summary":"Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(1.64) per share which missed the analyst consensus estimate of $(0.78) by 110.26 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38787547/benitec-biopharma-q3-2024-gaap-eps-1-64-misses-0-78-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC"],"gpt_icon":0},{"id":"2435160324","title":"Press Release: Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2435160324","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435160324?lang=en_us&edition=fundamental","pubTime":"2024-05-13 20:15","pubTimestamp":1715602500,"startTime":"0","endTime":"0","summary":"-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy  Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April-. -The Second OPMD Subject was Safely Dosed with BB-301 in February-. -Additional Interim Clinical Safety Data and Clinical Efficacy Data are Expected for Several Study Subjects in the Second Half of 2024-. -23 OPMD Subjects have Enrolled into the OPMD Natural History Study with Multiple Subjects Eligible for Entry into the BB-301 Phase 1b/2a Clinical Treatment Study-. \"The interim clinical trial results for the first subject enrolled onto the BB-301 Phase 1b/2a Clinical Treatment Study demonstrated consistent, clinically meaningful improvements in each of the central study endpoints, with significant improvements noted across the radiographic assessments of swallowing and corresponding improvements observed for the key subject-reported outcome measure,\" said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Ch","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","BK4167","BK4139","BK4547","NH","BNTC","BB"],"gpt_icon":0},{"id":"2434585353","title":"Benitec Biopharma Inc    expected to post a loss of 78 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2434585353","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434585353?lang=en_us&edition=fundamental","pubTime":"2024-05-10 20:18","pubTimestamp":1715343488,"startTime":"0","endTime":"0","summary":"* Benitec Biopharma Inc     is expected to show a fall in quarterly revenue when it reports  results on May 13 (estimated) for the period ending March 31 2024   *    * LSEG's mean analyst estimate for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC"],"gpt_icon":0},{"id":"2432573553","title":"Benitec Biopharma to Participate in the Citizens JMP Life Science Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2432573553","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2432573553?lang=en_us&edition=fundamental","pubTime":"2024-05-01 20:00","pubTimestamp":1714564800,"startTime":"0","endTime":"0","summary":"HAYWARD, Calif., May 01, 2024  -- Benitec Biopharma Inc.  , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference  platform, today announced that members of Benitec management will participate in Citizens JMP Life Science Conference, taking place in New York, NY from May 13-14, 2024.The Benitec presentation will also be available via live webcast here.Please contact your Citizens JMP representative to schedule a 1x1 meeting with Benitec management.Benitec Biopharma Inc.  is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype re","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wGa4eMZPcYrmKWNEWoa9rw--~B/aD0yNTQ7dz04MDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6420004cb8cbc8cbf0c4b9dec039e88f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wGa4eMZPcYrmKWNEWoa9rw--~B/aD0yNTQ7dz04MDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6420004cb8cbc8cbf0c4b9dec039e88f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/benitec-biopharma-participate-citizens-jmp-120000981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BNTC","BK4139","BK4127","JMP"],"gpt_icon":0},{"id":"2431182119","title":"BRIEF-Suvretta Capital Management Reports A Stake Of 19.99% In Benitec Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2431182119","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431182119?lang=en_us&edition=fundamental","pubTime":"2024-04-30 05:33","pubTimestamp":1714426409,"startTime":"0","endTime":"0","summary":"April 29 (Reuters) - Benitec Biopharma Inc   :   * SUVRETTA CAPITAL MANAGEMENT LLC REPORTS A STAKE OF 19.99% IN BENITEC BIOPHARMA AS OF APRIL 22, 2024Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4202","AS","BNTC","VIRI"],"gpt_icon":0},{"id":"2429995379","title":"Buy Rating Affirmed for Benitec Biopharma Following Promising BB-301 Trial Results and Financial Boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2429995379","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2429995379?lang=en_us&edition=fundamental","pubTime":"2024-04-22 12:35","pubTimestamp":1713760532,"startTime":"0","endTime":"0","summary":"In a report released today, Silvan Tuerkcan from JMP Securities reiterated a Buy rating on Benitec Biopharma (BNTC – Research Report), with a price...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-benitec-biopharma-following-promising-bb-301-trial-results-and-financial-boost?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-benitec-biopharma-following-promising-bb-301-trial-results-and-financial-boost?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BNTC"],"gpt_icon":0},{"id":"2428634910","title":"Benitec Biopharma’s $40 Million Equity Financing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2428634910","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2428634910?lang=en_us&edition=fundamental","pubTime":"2024-04-19 18:13","pubTimestamp":1713521602,"startTime":"0","endTime":"0","summary":"An update from Benitec Biopharma Ltd (BNTC) is now available. Benitec Biopharma Inc. has entered into a Securities Purchase Agreement on April 17, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/benitec-biopharmas-40-million-equity-financing-deal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/benitec-biopharmas-40-million-equity-financing-deal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","EQR","BK4139","BNTC","BK4215","BK4585"],"gpt_icon":0},{"id":"2428512614","title":"CGC, GENE and HOLO among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2428512614","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2428512614?lang=en_us&edition=fundamental","pubTime":"2024-04-19 00:42","pubTimestamp":1713458579,"startTime":"0","endTime":"0","summary":"Gainers: Bio-Path Holdings  +69%. Aileron Therapeutics  +51%. SINTX Technologies  +42%. Expion360  +30%. Swvl Holdings Corp  +27%. MicroCloud Hologram  +27%. Mawson Infrastructure Group  +26%. Benitec Biopharma  +26%. TH International Ltd.  +18%.  Canopy Growth Corporation  +19%.  Losers: WiSA Technologies  -34%. iLearningEngines  -29%. Edible Garden  -27%. Lithium Americas Corp  -27%. NRX Pharmaceuticals  -26%. Kartoon Studios  -25%. Genetic Technologies Ltd.  -25%. Aptorum Group Ltd  -25%. iClick Interactive Asia Group Ltd  -23%. Iczoom Group  -22%.   More on Mid-day movers & stocks.  Canopy Growth Is Climbing, But It Won't Last Canopy Growth Corporation  Q3 2024 Earnings Call Transcript Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come Canopy Growth stock traded in the red for the seventh day Canopy Growth to expedite entry into U.S. cannabis market","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4091132-cgc-gene-and-holo-among-mid-day-movers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4082","EDBL","BK4209","ALRN","BK4168","BK7505","BK4139","CGC","BK4585","THCH","AILE","BNTC","BK4557","HOLO","APM","BK4545","XPON","BK4121","BK7057","BPTH","BK4141","BK4096","BK4007","CGC.AU","ICLK","NRXP","BK4230","SINT","BK4189","MIGI","APM.AU","GENE","TOON","IZM","BK4595","WISA","BK4023","LAC","BK4140","BK4108","BK4009","BK4022","SWVL","BK7117"],"gpt_icon":0},{"id":"2428968235","title":"Benitec Biopharma Showcases Encouraging Clinical Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2428968235","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2428968235?lang=en_us&edition=fundamental","pubTime":"2024-04-18 21:02","pubTimestamp":1713445358,"startTime":"0","endTime":"0","summary":"An update from Benitec Biopharma Ltd (BNTC) is now available. Benitec Biopharma Inc. announced promising interim results from its BB-301 Phase 1b/2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/benitec-biopharma-showcases-encouraging-clinical-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/benitec-biopharma-showcases-encouraging-clinical-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","BK4547","BB","BK4139","BNTC"],"gpt_icon":0},{"id":"2428359611","title":"Benitec Biopharma reports positive data in early study for OPMD treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2428359611","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2428359611?lang=en_us&edition=fundamental","pubTime":"2024-04-18 20:55","pubTimestamp":1713444905,"startTime":"0","endTime":"0","summary":"Benitec Biopharma  announces positive data from 90-day time point following the administration of BB-301 to the study’s first subject treated in the BB-301 Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study in Oculopharyngeal Muscular Dystrophy. First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy.  BB-301 facilitated improvements across multiple measures of swallowing function in the first Phase 1b/2a clinical study subject as compared to pretreatment assessments conducted during the observational natural history portion of the study. Source: Press Release    More on Benitec  Netflix, Johnson & Johnson, Procter & Gamble And Baidu On Watch Benitec Biopharma jumps 33% on $40M private financing Seeking Alpha’s Quant Rating on Benitec Historical earnings data for Benitec Financial information for Benitec","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4090979-benitec-biopharma-reports-positive-data-in-early-study-for-opmd-treatment","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4581","NFLX","LU1548497426.USD","LU0719512351.SGD","LU2357305700.SGD","BK4524","BK4588","BK4507","BK4108","LU2326559502.SGD","SGXZ23171101.USD","BK4532","LU1046421795.USD","LU1429558221.USD","LU0082616367.USD","BK4585","LU1720051108.HKD","BK4551","BK4587","IE00B19Z9505.USD","BNTC","BK4566","BK4548","LU1435385759.SGD","BK4534","LU1720051017.SGD","BK4139","LU1989764664.SGD","SG9999004303.SGD","BK4527","LU1823568750.SGD"],"gpt_icon":0},{"id":"2428073593","title":"HOLO, SNTG and LRHC are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2428073593","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2428073593?lang=en_us&edition=fundamental","pubTime":"2024-04-18 20:40","pubTimestamp":1713444055,"startTime":"0","endTime":"0","summary":"Gainers: Bio-Path Holdings (BPTH) +61% Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients ","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4090954-holo-sntg-and-lrhc-are-among-premarket-gainers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IE00B3S45H60.SGD","IE0034235295.USD","IE0009356076.USD","SNTG","BK4538","BK4539","BK4535","LU0061474960.USD","LU0079474960.USD","IE00B1BXHZ80.USD","BNTC","MSFT","IE0004445239.USD","HOLO","KAVL","LU0061475181.USD","IE00BJTD4N35.SGD","VTSI","BK4007","LU0109391861.USD","AML.AU","BK4554","IE00BLSP4239.USD","BK7056","IE00BBT3K403.USD","BK4532","GB00B4LPDJ14.GBP","SXTC","LU0053666078.USD","IE00BJJMRX11.SGD","BK4533","BPTH","GB00B4QBRK32.GBP","GB00BDT5M118.USD","IE0034235188.USD","LRHC","IE00B19Z9505.USD","IE00B1XK9C88.USD","IE00B7KXQ091.USD","LU0082616367.USD","TWG","BK4209","THCH","YYAI","BK4548","IE00BKDWB100.SGD","MOB.AU","ZPTA","MOB","BK4534"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.benitec.com","stockEarnings":[{"period":"1week","weight":0.0075},{"period":"1month","weight":-0.0505},{"period":"3month","weight":0.3706},{"period":"6month","weight":1.2042},{"period":"1year","weight":0.7916},{"period":"ytd","weight":1.2489}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":0.0341},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1633},{"period":"1year","weight":0.2302},{"period":"ytd","weight":0.1473}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.06227},{"month":2,"riseRate":0.555556,"avgChangeRate":0.110444},{"month":3,"riseRate":0.777778,"avgChangeRate":0.056589},{"month":4,"riseRate":0.333333,"avgChangeRate":0.02399},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.070564},{"month":6,"riseRate":0.222222,"avgChangeRate":-0.119694},{"month":7,"riseRate":0.555556,"avgChangeRate":0.053998},{"month":8,"riseRate":0.25,"avgChangeRate":-0.041294},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.138675},{"month":10,"riseRate":0.555556,"avgChangeRate":-0.066768},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.064278},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.071947}],"exchange":"NASDAQ","name":"Benitec Biopharma","nameEN":"Benitec Biopharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Benitec Biopharma(BNTC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Benitec Biopharma,BNTC,Benitec Biopharma股票,Benitec Biopharma股票老虎,Benitec Biopharma股票老虎国际,Benitec Biopharma行情,Benitec Biopharma股票行情,Benitec Biopharma股价,Benitec Biopharma股市,Benitec Biopharma股票价格,Benitec Biopharma股票交易,Benitec Biopharma股票购买,Benitec Biopharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Benitec Biopharma(BNTC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}